Similar to the CLEOPATRA trial which showed a median PFS of 18.5 months with dual antibody combination treatment, the median PFS was similar at 19.5 months (95 % CI: 14 - 26) in the phase II trial (Dang et al. 2015) mentioned above.r Importantly, in the phase II trial, 32% of patients received prior trastuzumab, unlike the CLEOPATRA trial where only 10% patient had prior exposure to trastuzumab.
A summary of the efficacy at 6 months (n=69)* is shown below:
|Progression of disease
*Note: 64 patients were eligible for 6-month progression-free survival assessment. Five patients did not have scans at the 6- months time point: two came onto and off the study on the same day because of paclitaxel hypersensitivity; one came off the study and two were lost to follow-up before the 6-month time point and did not have imaging studies.r
(A) Progression-free survival (PFS) (B) PFS based on line of therapyr
© J Clin Oncol 2015
Preliminary analysis from the ongoing multicentre single-arm phase IIIb PERUSE study showed at 52 months median follow-up a median PFS of 20.6 months (95% CI: 18.9-22.7) overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively).r Overall response rate (ORR) was 80% (95% CI: 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). The median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane.